Endovalve is a cardiovascular device company developing a mitral valve replacement system that could provide sufferers of mitral regurgitation with a new, minimally invasive surgical option for early treatment of this progressive, increasingly prevalent disease. We are a venture-backed start-up that has demonstrated the functionality of the core design. During in-vivo tests, a prototype of its investigational valve functioned successfully for more than 30 minutes in each of four consecutive sheep.